Whole Genome Sequencing for personalized selection of experimental treatment of advanced solid cancer

M.A. Pruis¹, F.H. Groenendijk², K.S. Badloe³, A. van Puffelen¹, D. Robbrecht¹, W.N.M. Dinjens², S. Sleijfer¹, A.C. Dingemans³, J.H. von der Thüsen³, P. Roepman⁴, M.P. Lolkema¹

Departament of Medical Oncology¹, Pathology² and Pulmonary Medicine³, Erasmus MC Cancer Institute, Rotterdam, NL and Hartwig Medical Foundation⁴, Amsterdam, NL

Background

Trial specific pre-screenings tests are time and tissue consuming. This complicates personalized experimental treatment of patients who are eligible for early phase clinical trials. In this study, the feasibility of up-front whole genome sequencing (WGS) guided inclusion in early phase trials was investigated.

Results

From September 2019 – March 2021, 31 patients underwent a FF tumor biopsy for WGS (Table 1). The tumor types were highly diverse. Median turnaround time between biopsy and WGS reporting was 15 days (fig. 2). Two samples were not evaluable due to low tumor purity (fig. 3). In 84% of the patients (26/31) at least one actionable alteration or biomarker was found (fig. 4). A third of the patients (11/31) received matched experimental treatment. Reasons for not receiving matched treatment were: absence of a matching trial (n=8), rapid clinical deterioration (n=4) or other (n=2). IF showed tumors with low mutational burden could be highly inflammatory, with high CD8+ cell counts.

Patients and Methods

The Phase I Unit Molecular Tumor Board (MTB), Erasmus MC Cancer Institute reviewed patients with advanced cancer without standard-of-care treatment (SOC) options for eligibility for a fresh frozen (FF) tumor biopsy for WGS based on clinical-pathological features (fig. 1). The MTB consists of medical oncologists, pathologists, molecular biologists and clinical geneticists. WGS was performed by Hartwig Medical Foundation⁴. Actionability was reported using the ESCAT scale. Multiplex immunofluorescent staining (IF) was performed on simultaneously taken tumor tissue.

Conclusion

WGS on fresh frozen tumor biopsies is a feasible tool for the selection of personalized experimental therapy in patients with advanced cancer without SOC options. WGS could fulfill the role of universal up-front genomic pre-screening test, as WGS is now possible in an acceptable turnaround time (15 days) and the analysis pipeline is open-source. IF had additional value on determining immunogenicity.

Figure 1. Phase I unit molecular tumor board discussing patients for WGS on several considerations

Figure 2. Median time from biopsy to WGS reporting.

Table 1. Baseline patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>64 (20-81)</td>
</tr>
<tr>
<td>Median ECOG performance score</td>
<td>0 (0-2)</td>
</tr>
<tr>
<td>Median prognostic score</td>
<td>5 (0-14)</td>
</tr>
<tr>
<td>Median number of treatment lines (range)</td>
<td>4 (1-7)</td>
</tr>
<tr>
<td>Mean number of treated lines (range)</td>
<td>4 (1-8)</td>
</tr>
</tbody>
</table>

Figure 3. Results and treatment consequences of WGS analysis

Conclusion

WGS on fresh frozen tumor biopsies is a feasible tool for the selection of personalized experimental therapy in patients with advanced cancer without SOC options. WGS could fulfill the role of universal up-front genomic pre-screening test, as WGS is now possible in an acceptable turnaround time (15 days) and the analysis pipeline is open-source. IF had additional value on determining immunogenicity.

Figure 4. Actionable alterations according to ESCAT scale

Contact: Melinda Pruis
m.pruis@erasmusmc.nl

No conflicts of interest to declare

References:


95P